Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2003 1
2004 2
2005 1
2009 1
2010 3
2011 2
2012 2
2013 2
2014 3
2015 2
2016 2
2017 9
2018 10
2019 8
2020 20
2021 28
2022 32
2023 42
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: yang j. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
CRISP(e)R drug discovery.
Yang JH. Yang JH. Nat Chem Biol. 2022 May;18(5):435-436. doi: 10.1038/s41589-022-00979-8. Nat Chem Biol. 2022. PMID: 35197625 No abstract available.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: yang j. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
Antibiotic efficacy-context matters.
Yang JH, Bening SC, Collins JJ. Yang JH, et al. Curr Opin Microbiol. 2017 Oct;39:73-80. doi: 10.1016/j.mib.2017.09.002. Epub 2017 Oct 16. Curr Opin Microbiol. 2017. PMID: 29049930 Free PMC article. Review.
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.
Lee EHJ, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, Gumber D, Park AK, Young C, Monroy I, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chang WC, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ. Lee EHJ, et al. Among authors: yang j. Nat Commun. 2023 Aug 7;14(1):4737. doi: 10.1038/s41467-023-40115-1. Nat Commun. 2023. PMID: 37550294 Free PMC article.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: yang j. Nat Cancer. 2023 Jun;4(6):860-871. doi: 10.1038/s43018-023-00578-z. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322367 Clinical Trial.
Suicidal Ideation Among Patients with Gastrointestinal Cancer.
Katayama ES, Moazzam Z, Woldesenbet S, Lima HA, Endo Y, Azap L, Yang J, Dillhoff M, Ejaz A, Cloyd J, Pawlik TM. Katayama ES, et al. Among authors: yang j. Ann Surg Oncol. 2023 Jul;30(7):3929-3938. doi: 10.1245/s10434-023-13471-x. Epub 2023 Apr 16. Ann Surg Oncol. 2023. PMID: 37061648
159 results